Home > Healthcare > Drug Device Combination > Therapeutic Systems > Long QT Syndrome Treatment Market

Long QT Syndrome Treatment Market Trends

Report ID: GMI8775
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Long QT Syndrome Treatment Market Trends

The rising incidence of arrhythmia and the increasing uptake of electrophysiology interventions are driving the expansion of the LQTS treatment market. The most common arrhythmia poses risks such as heart failure, stroke, and peripheral embolization. Therefore, electrophysiology procedures, such as implantable cardioverter-defibrillator (ICD) implantation and cardiac ablation, are key interventions used to manage arrhythmias associated with LQTS. Thus, aforementioned factors are anticipated to accelerate the market growth.

However, high cost of surgical procedure may hamper the market growth to certain extent.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Long QT syndrome treatment market size was USD 2.1 billion in 2023 and is expected to register 6.8% CAGR from 2024-2032 owing to the increasing frequency of genetic abnormalities that can interfere with the normal movement of ions worldwide.

Long QT syndrome treatment industry from the long QT syndrome type 1 segment recorded 33.1% share in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to increasing accessibility and affordability of genetic testing technologies.

North America long QT syndrome treatment industry reached USD 892.8 million in 2023 and is expected to register a commendable CAGR from 2024-2032 due to adoption of electrophysiology procedures in the region.

Abbott Laboratories, AstraZeneca, Bayer AG, Boehringer Ingelheim, Boston Scientific Corporation, Bristol Myers Squibb, GSK plc, Medtronic Plc, Merck & Co., Inc., Pfizer Inc., and Sanofi, are some of the major long QT syndrome treatment companies worldwide.